Team:TU-Delft/Peptides

(Difference between revisions)

Content

Peptide Production
SUMO-Peptide Production
SUMO cleavage by Ulp1

Peptide production

The era of antibiotics are now outdated as the microorganisms started gaining new resistance mechanism to evade the effects of antibiotics. Nowadays more and more researches are focused towards new antimicrobial that can be more effective against these pathogens.

The antimicrobial peptides (AMP), natural or de-novo are becoming more popular due to their potential to kill or restrict the growth of microorganisms. They form a part of chemical defense against predators. All organisms, including higher order eukaryotes have some antimicrobial peptides that acts against specific strains of microorganisms.They are usually charged and interact with the opposite charges present on the membrane thus boring a hole through the membrane subsequently lysing the cell [1].Unlike, antibiotics they do not interfere in the genetic, transcriptional or translational machinery of the cells.

We chose 3 AMP that are produced in the skins of toads and frogs. They are magainin (GIGKFLHSAKKFGKAFVGQIMNS) from Xenopus laevis , signiferin (IIGHLIKTALGMLGL) from Crinia signifera and maximin-H5 (ILGPVLGLVSDTLDDVLGIL) from Bombina maxima. The reasons for choosing these AMP are because of their target specific nature, charge and length. They do not affect humans, which makes them a suitable candidate as pharmaceuticals [2].

The recombinant production of these peptides in E.coli would help large scale production of these peptides and administer them as antimicrobials. But, the major hurdle in producing them in vivo is the formation of inclusion bodies as they are charged. This could be overcome by making protein fusion with SUMO (Small Ubiquitin like Modifier), MBP (Maltose Binding Protein), Trx (Thioredoxin) etc.

In this project, a SUMO-peptide fusion was opted [3] as a suitable expression system as they make the fusion proteins more soluble. The Ulp-1 cleaving the fusion is a special protease that can cleave of the fusion without leaving any scar. This protease is also expressed and controlled by a negative transcriptional cascade. As the fusion is produced it triggers a cascade that ultimately leads to the expression of Ulp-1 and facilitates in vivo cleavage. This fusion increases the solubility of the peptide and reduces inclusion bodies formation.(Figure 1).

Figure 1: Schematic diagram of the peptide production

SUMO-Peptide Production

Aim: Increasing solubility of peptide with Sumo Fusion.
Description

The peptide by itself is not soluble in the cytoplasm but making a fusion of peptide with Small Ubiquitin like Modifiers (SUMO) will increase the solubility of the peptide, thus increasing the cytoplasmic fraction of the peptide.

A gene was constructed in such a way that the SUMO-peptide production was driven by the strong T7 phage promoter. This gene containing plasmid was harboured in a BL21(DE3) strain that has lac promoter driven T7 polymerase. Upon induction by IPTG the SUMO peptide fusion is produced as a soluble protein fraction.

Figure 2: Part BBa_K1022101/2/3

The protocol can be seen here.

Results

The presence of plasmid with gene inserts encoding the SUMO-peptide ( BBa_K1022101, BBa_K1022102,BBa_K1022103) was confirmed by a colony pcr. The expected size of the insert with the T7 promoter was approximately around 400 bp which was clearly evident from the agarose gel picture Fig (agarose). An Eurogentec Smartladder MW-1700-10 (https://secure.eurogentec.com/uploads/TDS-MW-1700-10.pdf) was used to identify the size of the fragments.

Discussion

SUMO cleavage by Ulp1